LGM Pharma Expands Analytical Services
The company is making a significant investment of over $2 million to enhance its analytical testing services and expand its manufacturing capabilities to include suppositories.
LGM Pharma, a contract development and manufacturing organization (CDMO), recently shared exciting news. On March 13, 2024, they announced a significant investment of over $2 million in their analytical testing services. This investment will allow them to expand their offerings by an impressive 50%. The company is also expanding its facility in Rosenburg, Texas and adding suppository manufacturing capabilities. These improvements will provide the company's customers with a more efficient and thorough manufacturing experience.
The Rosenburg facility has recently incorporated suppository drug delivery systems, which have been gaining popularity in the industry. The company states that suppository drug delivery systems offer improved drug absorption and precise drug release kinetics. These systems are particularly effective for high medication concentrations and extended drug release times. They offer a great solution for patients who struggle with swallowing pills or who experience nausea, as well as for chronic conditions and women's health.
In a recent company press release, Ian Gibson, executive vice president of operations at LGM Pharma, emphasized the importance of having CDMO partners with specialized capabilities in order to meet the increasingly diverse needs of patients in the pharmaceutical industry. Our team's extensive knowledge in suppository formulation development and manufacturing, along with our expertise in advanced delivery systems, showcases our commitment to offering strategic solutions to our industry partners.
The CDMO offers a range of analytical testing services, including method development, validation services, and stability testing. The company's facility in Irvine, California provides a wide range of chromatography and spectroscopy instrumentation. Furthermore, the company offers API sourcing and procurement, formulation development, and raw material and finished product testing and packaging.
According to Prasad Raje, CEO at LGM Pharma, the addition of standalone analytical testing allows the company to better serve their pharmaceutical partners by offering more flexibility to meet their specific product requirements. Through their comprehensive range of specialized assistance, they empower pharmaceutical companies to expedite their market entry and attain long-term prosperity in the current intricate market.
The company adopts a comprehensive, interdisciplinary approach to tackle our customers' most intricate analytical requirements. The team is made up of over 60 highly skilled specialists with extensive experience in analytical testing, method development, and validation.
LGM Pharma is excited to announce that it will be presenting its ATS and CDMO services at the upcoming 2024 DCAT Week, taking place from March 18–21 in the vibrant city of New York. We look forward to sharing our expertise and solutions with attendees.
Source: LGM Pharma
